With the ultimate goal to develop a targeted therapy, we developed anti‐PSMA decorated LNPs encapsulating Cy5‐labeled EGFP mRNA for specific and enhanced transfection in PSMA+ cancer cells. Here, FOLH1 is linked to cancer.